Rein Therapeutics director buys 47,060 RNTX shares
Rein Therapeutics director Josef H. von Rickenbach reported a series of open-market purchases of Rein Therapeutics, Inc. common stock.
Rhea-AI Filing Summary
Rein Therapeutics director Josef H. von Rickenbach reported a series of open-market purchases of Rein Therapeutics, Inc. common stock. Between May 21 and May 27, 2026, he bought a total of 47,060 shares at weighted average prices slightly above $1.00 per share.
The individual purchases were 3,420 shares at $1.0422 on May 21, 15,950 shares at $1.0475 on May 22, 23,190 shares at $1.0552 on May 26, and 4,500 shares at $1.0708 on May 27, all as non-derivative common stock transactions. Following these purchases, he directly owns 62,514 shares of Rein Therapeutics common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 47,060 shares
Net Buy
4 txns
Insider
VON RICKENBACH JOSEF H
Role
Director
Bought
47,060 shs ($50K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common stock , $0.001 par value | 4,500 | $1.0708 | $5K |
| Purchase | Common stock , $0.001 par value | 23,190 | $1.0552 | $24K |
| Purchase | Common stock , $0.001 par value | 15,950 | $1.0475 | $17K |
| Purchase | Common stock , $0.001 par value | 3,420 | $1.0422 | $4K |
Holdings After Transaction:
Common stock , $0.001 par value — 62,514 shares (Direct)
Footnotes (1)
- F1. The reported shares were purchased in the open market in multiple transactions at prices ranging from $1.05 and $1.035 on May 21, 2026, $1.07 and $1.01 on May 22, 2026, $1.07 and $1.03 on May 26, 2026 and $1.08 and $1.03 on May 27, 2026. The prices reported in Column 4 are a weighted average price for purchase on the respective day. The reporting person undertakes to provide to Rein Therapeutics, Inc., any stockholder of Rein Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1).
Key Figures
May 21 purchase: 3,420 shares at $1.0422
May 22 purchase: 15,950 shares at $1.0475
May 26 purchase: 23,190 shares at $1.0552
+3 more
6 metrics
May 21 purchase
3,420 shares at $1.0422
Open-market common stock purchase on May 21, 2026
May 22 purchase
15,950 shares at $1.0475
Open-market common stock purchase on May 22, 2026
May 26 purchase
23,190 shares at $1.0552
Open-market common stock purchase on May 26, 2026
May 27 purchase
4,500 shares at $1.0708
Open-market common stock purchase on May 27, 2026
Post-transaction holdings
62,514 shares
Direct common stock ownership after May 27, 2026 trade
Net buy shares
47,060 shares
Net-buy activity summarized across four transactions
Key Terms
open-market purchase, non-derivative, weighted average price, multiple transactions
4 terms
open-market purchase financial
"transaction_action: "open-market purchase" for each common stock transaction"
An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.
non-derivative financial
"transaction_type: "non-derivative" for all reported common stock trades"
weighted average price financial
"The prices reported in Column 4 are a weighted average price for purchase on the respective day."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
multiple transactions financial
"purchased in the open market in multiple transactions at prices ranging from $1.05 and $1.035..."
FAQ
What insider activity did Rein Therapeutics (RNTX) report for Josef H. von Rickenbach?
Rein Therapeutics reported that director Josef H. von Rickenbach bought common stock in four open-market transactions. These non-derivative purchases occurred between May 21 and May 27, 2026, increasing his directly held position in Rein Therapeutics common shares.
At what prices did Josef H. von Rickenbach buy RNTX stock?
The reported weighted average prices per share were $1.0422, $1.0475, $1.0552, and $1.0708. A footnote explains these averages reflect multiple trades within daily price ranges slightly above $1.00 per share during May 21–27, 2026.
Were derivatives involved in Josef H. von Rickenbach’s recent RNTX transactions?
No, the reported transactions all involve non-derivative common stock. The Form 4 classifies each as an open-market purchase of common stock, and the derivative holdings summary shows no remaining derivative positions reported in this particular filing.
How many buy and sell transactions did the Rein Therapeutics (RNTX) Form 4 summarize?
The transaction summary lists four buy transactions and zero sales. It shows net-buy activity of 47,060 shares, with no exercises, gifts, tax withholdings, or restructuring-related transfers disclosed in this Form 4 filing.
AI-generated analysis. How Rhea-AI works. Not financial advice.
